963-74-6

Basic information

• Product Name: 5ALPHA-ANDROSTAN-17-ONE
• Synonyms: 17-KETO-5-ALPHA-ANDROSTANE;5ALPHA-ANDROSTAN-17-ONE;5A-ANDROSTAN-17-ONE;5A-ANDROSTANONE;ANDROSTAN-17-ONE, 5A-;17-Oxo-5alpha-androstane;Androstan-17-one;5α-Androstan-17-one
• CAS NO: 963-74-6
• Molecular Formula: C₁₉H₃₀O
• Molecular Weight: 274.44
• EINECS: 213-516-8
• Product Categories: Steroids
• Mol File: 963-74-6.mol
• Article Data: 31

Chemical Properties

• Boiling Point: 368.5 °C at 760 mmHg
• Flash Point: 168.7 °C
• Appearance: /
• Density: 1.014 g/cm³
• Vapor Pressure: 1.27E-05mmHg at 25°C
• Refractive Index: 1.517
• Storage Temp.: -20°C Freezer, Under inert atmosphere
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• CAS DataBase Reference: 5ALPHA-ANDROSTAN-17-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 5ALPHA-ANDROSTAN-17-ONE(963-74-6)
• EPA Substance Registry System: 5ALPHA-ANDROSTAN-17-ONE(963-74-6)

Safety Data

• Hazardous Substances Data: 963-74-6(Hazardous Substances Data)

Usage

General Description

5ALPHA-ANDROSTAN-17-ONE, also known as 5α-androst-17-one or etiocholanolone, is a steroid hormone and a metabolite of testosterone and dihydrotestosterone. It is produced in the adrenal glands, as well as in the brain and gonads, and is involved in the regulation of stress response and mood. It is also a precursor to the androgen and estrogen hormones. 5ALPHA-ANDROSTAN-17-ONE has been studied for its potential role in various physiological processes and conditions, including stress, anxiety, and mood disorders, as well as its potential as a biomarker for certain neurological and psychiatric disorders. Additionally, it has been investigated for its potential use as a dietary supplement for improving performance and muscle strength.

InChI:InChI=1/C19H30O/c1-18-11-4-3-5-13(18)6-7-14-15-8-9-17(20)19(15,2)12-10-16(14)18/h13-16H,3-12H2,1-2H3/t13-,14+,15+,16+,18+,19+/m1/s1

Upstream product

• 158299-72-0 Acetyl-thiocarbamic acid O-((3R,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-17-oxo-hexadecahydro-cyclopenta[a]phenanthren-3-yl) ester 
• 481-21-0 cholestane 
• 64-19-7 acetic acid 
• 53-43-0 dehydroepiandrosterone 
• 75-18-3 dimethylsulfide 
• 42723-49-9 7-methyl-13-(2-methyl-4-hydroxy-2-cyclohexenyl)-trans,trans-6,10-tridecadien-2-yne 
• 1225-43-0 (5R,8R,9S,10S,13S,14S,17S)-10,13-Dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-ol 
• 148773-59-5 3α-(phenylthio)androstan-17-one 
• 95975-21-6 (5R,8R,9S,10S,13S,14S)-10,13-Dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-ol 
• 50633-62-0 3β,4β-diacetoxyandrost-5-en-17-one 
• 846-46-8 androstanedione 
• 481-20-9 5β-cholestane 
• 1912-63-6 androsta-3,5-dien-17-one 
• 14639-79-3 5α-androst-2-en-17-one 

Downstream Products

• 963-74-6 5β,13α-androstan-17-one 
• 19037-37-7 (5α)androstanol-17α 
• 56051-42-4 17β-Methyl-5α-androstanon-(16) 
• 35575-54-3 D-Bishomo-5α-androstan 
• 112859-74-2 16α-fluoro-5α-androstan-17-one 
• 13482-30-9 5α-Androstan-1,6-dion 
• 35493-99-3 4-Nitro-benzoic acid (5R,8R,9S,10S,13S,14S,16S)-10,13-dimethyl-17-oxo-hexadecahydro-cyclopenta[a]phenanthren-16-yl ester 
• 25831-00-9 16-Benzyliden-5α-androstan 
• 25831-02-1 16β-Benzyl-5α-androstan-17-on 
• 25831-03-2 17β-Hydroxy-16-benzyliden-5α-androstan 
• 127995-38-4 5α,17βH-pregnan-17-ol 
• 17291-32-6 5α-androstan-17β-yl-4-toluenesulfonate 
• 438-22-2 (5α)-androstane 
• 112344-75-9 methyl 17-nor-5α,13α-androstane-16β-carboxylate 

Relevant articles and documents

Defunctionalization of sp3 C–Heteroatom and sp3 C–C Bonds Enabled by Photoexcited Triplet Ketone Catalysts

A general strategy for enabling a light-induced defunctionalization of sp3 C–heteroatom and sp3 C–C bonds with triplet ketone catalysts and bipyridine additives is disclosed. This protocol is characterized by its broad scope without recourse to transition metal catalysts or stoichiometric exogeneous reductants, thus offering a complementary technique for activating σ sp3 C–C(heteroatom) bonds. Preliminary mechanistic studies suggest that the presence of 2,2′-bipyridines improves the lifetime of ketyl radical intermediates.

Method for hydrogenolysis of halides

The invention discloses a method for hydrogenolysis of halides. The invention discloses a preparation method of a compound represented by a formula I. The preparation method comprises the following step: in a polar aprotic solvent, zinc, H2O and a compound represented by a formula II are subjected to a reaction as shown in the specification, wherein X is halogen; Y is -CHRR or R; hydrogenin H2O exists in the form of natural abundance or non-natural abundance. According to the preparation method, halide hydrogenolysis can be simply, conveniently and efficiently achieved through a simple and mild reaction system, and good functional group compatibility and substrate universality are achieved.

Dehalogenative Deuteration of Unactivated Alkyl Halides Using D2O as the Deuterium Source

The general dehalogenation of alkyl halides with zinc using D2O or H2O as a deuterium or hydrogen donor has been developed. The method provides an efficient and economic protocol for deuterium-labeled derivatives with a wide substrate scope under mild reaction conditions. Mechanistic studies indicated that a radical process is involved for the formation of organozinc intermediates. The facile hydrolysis of the organozinc intermediates provides the driving force for this transformation.